Q-omics provides the consensus-scored ZNF273 profile across patient tissues and cancer cell-line models. ZNF273 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ZNF273 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ZNF273 RNA expression shows 20,739 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, KIRP, and UVM as cancer lineages where ZNF273 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF273 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF273 survival associations across molecular data types. ZNF273 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF273 RNA expression–survival associations across cancer types. High ZNF273 expression shows unfavorable associations in KICH, ACC, UVM, LGG and UCEC, but favorable associations in SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ZNF273 RNA expression.
This table summarizes ZNF273 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF273. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF273 shows lower tumor expression in THCA and higher tumor expression in KIRP, BLCA, LUSC, LIHC and BRCA. The KIRP box plot shows higher ZNF273 RNA expression in tumor versus normal tissue (log2 FC = +1.065, t-test p < 0.001).
This table shows molecular features associated with ZNF273 in patient tissues and cancer cell lines. In patient samples, ZNF273 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF273 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
